dc.creatorVazquez, Leonardo
dc.creatorFerreira, Andre Teixeira da Silva
dc.creatorCavalcante, Fernanda Sampaio
dc.creatorGarcia, Israel José P.
dc.creatorSantos, Katia Regina Netto dos
dc.creatorBarbosa, Leandro Augusto de Oliveira
dc.creatorAlmeida, Marcius da Silva
dc.creatorMignaco, Julio Alberto
dc.creatorFontes, Carlos Frederico Leite
dc.date2019-05-14T16:13:36Z
dc.date2019-05-14T16:13:36Z
dc.date2018
dc.date.accessioned2023-09-26T20:14:55Z
dc.date.available2023-09-26T20:14:55Z
dc.identifierVAZQUEZ, Leonardo et al. Properties of novel surfactin‐derived biosurfactants obtained through solid‐phase synthesis. Journal of Peptide Science, v. 24, p.1-13, 2018.
dc.identifier1075-2617
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/33068
dc.identifier10.1002/psc.3129
dc.identifier1099-1387
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8852413
dc.descriptionEight molecules, four peptides (SPs) and four lipopeptides (LPs) derived by rational design from surfactin, a well-known secreted biosurfactant from Bacillus subtilis, were produced employing Fmoc-based solid-phase synthesis. These new peptides were tested to evaluate their potential biosurfactant and biological activities, aiming at possible applications in industrial, biological, pharmaceutical, and medical use. Five molecules (SP1, SP2, SP4, LP5, and LP8) presented potential for medical uses, mainly due to their drug delivery properties as suggested by their synergistic activity with the antibiotic vancomycin against Staphylococcus aureus. All synthetic peptides showed low toxicity against Vero cell cultures, in assays of hemolysis, and in different cytotoxicity assays. In addition, we found that three peptides (SP1, LP6, and LP7) had potential technological and industrial use because of their emulsifying capacity, low toxicity, and ability to physically stabilize solutions. These novel molecules retained some properties of the parental molecule (surfactin, which was originally obtained through nonribosomal synthesis in Bacillus subtilis) but have the advantage of being linear peptides, which can be produced at large scales through the use of conventional heterologous protein expression protocols.
dc.description2022-01-01
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsrestricted access
dc.subjectPeptídeo
dc.subjectBiosurfactantes
dc.subjectEntrega de drogas
dc.subjectSíntese de fase sólida
dc.subjectDesign racional
dc.subjectSurfactina
dc.subjectEfeito sinérgico
dc.subjectBiosurfactants
dc.subjectDrug delivery
dc.subjectLinear peptides
dc.subjectLipopeptides
dc.subjectPeptide
dc.subjectRational design
dc.subjectSolid‐phase synthesis
dc.subjectSurfactin
dc.subjectSynergistic effect
dc.subjectLipopeptídeos
dc.titleProperties of novel surfactin-derived biosurfactants obtained through solid-phase synthesis
dc.typeArticle


Este ítem pertenece a la siguiente institución